4.6 Article

Loxl2 is dispensable for dermal development, homeostasis and tumour stroma formation

Journal

PLOS ONE
Volume 13, Issue 6, Pages -

Publisher

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0199679

Keywords

-

Funding

  1. Medical Research Council [G1100073]
  2. Cancer Research UK [C219/A23522]
  3. Wellcome Trust [096540/Z/11/Z]
  4. Spanish Ministry of Economy and Innovation [SAF2016-76504-R]
  5. Institute de Salud Carlos III (RTICC) [RD12/0036/0007, CB16/12/00295]
  6. Worldwide Cancer Research [12-1057]
  7. EMBO long-term fellowship [aALTF594-2014]
  8. EMBO Advanced Fellowship [aALTF 523-2017]
  9. Finnish Cultural Foundation Fellowship
  10. Research Training Group Hallmarks of Skin Cancer of the German Research Foundation (Deutsche Forschungsgemeinschaft/DFG) [RTG2099, GTK2099/RT2099, 3]
  11. German Research Foundation (Deutsche Forschungsgemeinschaft/DFG) [GRK2099/RTG2099, 7]
  12. Engineering and Physical Sciences Research Council [EP/K00641X/1, EP/M022536/1]
  13. Nikon Imaging Centre at KCL and of the Light Microscopy Core Facility at DKFZ
  14. Department of Health via the National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre award
  15. King's College Hospital NHS Foundation Trust
  16. Engineering and Physical Sciences Research Council [EP/M507222/1] Funding Source: researchfish
  17. EPSRC [EP/K00641X/1, EP/M507222/1, EP/M022536/1] Funding Source: UKRI
  18. MRC [G1100073] Funding Source: UKRI

Ask authors/readers for more resources

Lysyl oxidase-like 2 (LOXL2) is a copper-dependent monoamine oxidase that contributes to the remodelling of the extracellular matrix (ECM) by cross linkage of collagen and elastin fibres and has emerged as a potential therapeutic target in cancer and fibrosis. In the skin, LOXL2 is essential for epidermal cell polarity and differentiation. However, its role in the dermis has not been evaluated. We found that Loxl2 is dispensable for mouse dermal development, maturation and homeostasis, yet affects dermal stiffness. Neither loss of Loxl2 nor increased Loxl2 expression affected dermal architecture following treatment with the phorbol ester TPA. Furthermore, Loxl2 expression did not alter the stroma of DMBA-TPA-induced tumours. We conclude that, although Loxl2 is expressed in both dermis and epidermis, its function appears largely confined to the epidermis.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available